Released · Last reviewed
GLP-1 eligibility checker
An educational self-check of common GLP-1 eligibility factors. Not a diagnosis or guarantee of treatment.
This is an educational self-check, not a medical assessment. Only a licensed clinician can determine eligibility.
- ☐ BMI ≥ 30, or ≥ 27 with a weight-related condition (general threshold)
- ☐ No personal or family history of medullary thyroid carcinoma or MEN 2
- ☐ Not pregnant or planning pregnancy
- ☐ No history of pancreatitis without clinician clearance
- ☐ Willing to complete a clinical intake and follow-up
Meeting these does not guarantee a prescription; a clinician reviews your full history.
Jastreboff AM et al., N Engl J Med 2022 (NCT04184622), n=2,539. Dose-response is real: the effect rises with dose. These are FDA-APPROVED SUBCUTANEOUS INJECTION doses — they do not transfer to compounded, microdose or ODT products. Trial means are not individual promises.
What this tool calculates, and the formula behind it
Every figure this tool produces uses the same formula as our editorial pages, drawn from the same dataset. There is no separate “marketing” number.
Effective monthly cost = total mandatory payments ÷ months supplied.
| Input | Why it counts |
|---|---|
| Advertised price | The starting point — and usually the most misleading number available. |
| Number of months | A 12-month plan and a month-to-month plan are not the same product. |
| Membership fee | If you cannot decline it, it is part of the price. Roughly half the market splits it out. |
| Consultation fee | Charged separately by some providers; invisible in most comparison tables. |
| Laboratory fee | Some programmes require labs and bill them; others include them. |
| Shipping | Free at some providers, billed at others. |
| Onboarding fee | A one-off charge that is amortised across the plan, not ignored. |
| Dose surcharge | The big one. A flat-rate programme and an escalating one can differ by thousands a year at maintenance. |
| Renewal price | What you pay from month two. This is the number that matters. |
| Discount / coupon | Applied only where the eligibility is stated. |
Assumptions and limitations
- Assumes you complete the plan. Early cancellation terms vary enormously and are not modelled — get them in writing before committing.
- Assumes the advertised ongoing price is accurate. Where we have not captured a price ourselves it is labelled Reported, not Verified.
- Does not model a dose change mid-plan on an escalating programme — ask the provider what you will pay at your target maintenance dose.
- Does not model insurance. If your plan covers brand Zepbound, the savings card can bring it to roughly $25/month, which beats every cash option here.
Privacy
This tool runs entirely in your browser. Nothing you enter is transmitted, stored or logged. We do not collect health information through any tool, form or search on this site.
Frequently asked questions
Are these prices verified?
Provider prices shown in our tools are captured from provider sites and major publishers and labeled with a verification status and date. Only first-party captures are marked Verified; always confirm current pricing on the provider’s own site before enrolling.
Does this tool give medical advice?
No. Our calculators and checklists are educational and help you compare cost and program features. Eligibility and treatment decisions are made by a licensed clinician.
How is effective monthly cost calculated?
Total mandatory payments for the treatment period — medication plus required membership, labs, shipping, onboarding, and dose surcharges — divided by months supplied. See our affordability methodology.
What this eligibility checker does and does not do
This checker reflects the general clinical thresholds most telehealth programs and FDA labels use: a body mass index of 30 or higher, or 27–29.9 with at least one weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnea. It provides an educational indication of whether you may meet common eligibility criteria.
Why only a licensed clinician can determine eligibility
Meeting a BMI threshold is necessary but not sufficient. A licensed provider must review your full medical history, current medications, and contraindications — including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pancreatitis, and pregnancy — before determining whether semaglutide is appropriate. This tool cannot make that determination and does not establish a provider-patient relationship. Eligibility is decided by a clinician, not by a calculator.
Limitations
The thresholds shown are general and may differ by program, state, and indication. Some programs use a BMI floor as low as 27 with a comorbidity; others require higher. This tool does not collect or store the values you enter, provides no diagnosis, and is not a substitute for professional medical evaluation. Last reviewed September 2026.
Sources: FDA — human drug compounding and GLP-1 status; clinical evidence via NEJM. Pricing captured September 2026; see evidence ledger. Last reviewed September 2026.
The numbers behind this page
How this tool is kept current
Every price quoted in this tool comes from the programme's own pricing page and carries the date it was captured. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
Why the spread is this wide
The figures in this tool sit inside a market with a measurable shape, and that shape is what makes any single price readable.
The molecule is chemically identical across every programme in the range. The $230 a month between the lowest and highest all-in semaglutide prices we read on October 15, 2026 ($49 and $279) is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We compare programs on their lowest all-in monthly price and print the plan term beside every figure, so a rate that needs a commitment is labelled as one.
Where do these prices come from?
Each is read from the program's own pricing page and carries its read date. The October 15, 2026 file at /api/prices.json holds 106 records, 49 of them verified standard-dose prices, with molecule, dose class and evidence status on every record.
Which tracked programs charge less than NexLife?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.